Atlas Trials

Dry Age-related Macular Degeneration

52 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Dry Age-related Macular Degeneration

RecordFirmDate
Observation of the Natural Course of Age-related Macular Degeneration (NCT05418231)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine2022-07-01
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT) (NCT05447650)i-Lumen Scientific, Inc.2022-04-12
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) (NCT04627428)Luxa Biotechnology, LLC2022-04-05
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) (NCT04358471)Hemera Biosciences2021-07-31
Microcurrent Stimulation for Dry Age-related Macular Degeneration (NCT04511936)i-Lumen Scientific, Inc.2021-03-01
CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration (NCT04636853)Fondazione Policlinico Universitario Agostino Gemelli IRCCS2020-12-23
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (NCT04566445)Gyroscope Therapeutics Limited2020-09-28
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration (NCT04339764)National Eye Institute (NEI)2020-09-23
Observational Study of Vision Improvement in Late Stage Dry AMD Patients (NCT04349254)Optimal Acuity Corporation2020-08-14
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration (NCT04643886)Gemini Therapeutics, Inc.2020-07-30
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration (NCT04246866)Gemini Therapeutics, Inc.2019-12-19
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) (NCT04065490)LumiThera, Inc.2019-09-01
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (NCT04437368)Gyroscope Therapeutics Limited2019-04-26
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II) (NCT03878420)LumiThera, Inc.2019-02-14
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) (NCT03894020)Gyroscope Therapeutics Limited2019-01-08
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD (NCT03846193)Gyroscope Therapeutics Limited2018-12-17
PRIMA US-Feasibility Study in Atrophic Dry AMD (NCT03392324)Science Corporation2018-04-26
Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases (NCT02755428)Chinese Academy of Sciences2018-01-01
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration (NCT03333954)Science Corporation2017-11-06
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells (NCT03046407)Chinese Academy of Sciences2017-09-06
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration (NCT03626636)Allegro Ophthalmics, LLC2017-08-01
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 (NCT03144999)Janssen Research & Development, LLC2017-03-29
The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD (NCT03305029)CHA University2016-05-01
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (NCT02686658)IVERIC bio, Inc.2015-12-15
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD (NCT01674829)CHABiotech CO., Ltd2012-09-01
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (NCT01344993)Astellas Institute for Regenerative Medicine2011-06-09
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration (NCT01379560)Sucampo Pharma Americas, LLC2011-05-01
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy (NCT01002950)Kubota Vision Inc.2009-10-01
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration (NCT00950638)Ophthotech Corporation2009-07-16
Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD (NCT00926861)The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery2009-07-01
Transcorneal Electrical Stimulation Therapy for Retinal Disease (NCT00804102)Okuvision GmbH2008-01-01
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration (NCT00541333)The New York Eye & Ear Infirmary2007-12-01
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration (NCT00429936)Sirion Therapeutics, Inc.2006-12-01
Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial (NCT00751361)Apheresis Research Institute1998-11-01

Track Dry Age-related Macular Degeneration automatically

Every clearance here is in the API, with alerts when new ones post.